As the most common cancer in women, efforts have been made to develop novel nanomedicine-based therapeutics for breast cancer. In the present study, the in silico curcumin (Cur) properties were investigated, and we found some important drawbacks of Cur. To enhance cancer therapeutics of Cur, three different nonionic surfactants (span 20, 60, and 80) were used to prepare various Cur-loaded niosomes (Nio-Cur). Then, fabricated Nio-Cur were decorated with folic acid (FA) and polyethylene glycol (PEG) for breast cancer suppression. For PEG-FA@Nio-Cur, the gene expression levels of Bax and p53 were higher compared to free drug and Nio-Cur. With PEG-FA-decorated Nio-Cur, levels of Bcl2 were lower than the free drug and Nio-Cur. When MCF7 and 4T1 cell uptake tests of PEG-FA@Nio-Cur and Nio-Cur were investigated, the results showed that the PEG-FA-modified niosomes exhibited the most preponderant endocytosis. In vitro experiments demonstrate that PEG-FA@Nio-Cur is a promising strategy for the delivery of Cur in breast cancer therapy. Breast cancer cells absorbed the prepared nanoformulations and exhibited sustained drug release characteristics.

Folate-Targeted Curcumin-Loaded Niosomes for Site-Specific Delivery in Breast Cancer Treatment: In Silico and In Vitro Study

Matencio Duran, Adrian;Trotta, Francesco;
2022-01-01

Abstract

As the most common cancer in women, efforts have been made to develop novel nanomedicine-based therapeutics for breast cancer. In the present study, the in silico curcumin (Cur) properties were investigated, and we found some important drawbacks of Cur. To enhance cancer therapeutics of Cur, three different nonionic surfactants (span 20, 60, and 80) were used to prepare various Cur-loaded niosomes (Nio-Cur). Then, fabricated Nio-Cur were decorated with folic acid (FA) and polyethylene glycol (PEG) for breast cancer suppression. For PEG-FA@Nio-Cur, the gene expression levels of Bax and p53 were higher compared to free drug and Nio-Cur. With PEG-FA-decorated Nio-Cur, levels of Bcl2 were lower than the free drug and Nio-Cur. When MCF7 and 4T1 cell uptake tests of PEG-FA@Nio-Cur and Nio-Cur were investigated, the results showed that the PEG-FA-modified niosomes exhibited the most preponderant endocytosis. In vitro experiments demonstrate that PEG-FA@Nio-Cur is a promising strategy for the delivery of Cur in breast cancer therapy. Breast cancer cells absorbed the prepared nanoformulations and exhibited sustained drug release characteristics.
2022
27
14
4634
4654
ADME prediction; PEG; breast cancer; curcumin; endocytosis; folic acid; in silico studies; molecular docking; niosome; Drug Carriers; Drug Delivery Systems; Female; Folic Acid; Humans; Liposomes; Polyethylene Glycols; Breast Neoplasms; Curcumin; Nanoparticles
Honarvari, Banafsheh; Karimifard, Sara; Akhtari, Niyayesh; Mehrarya, Mehrnoush; Moghaddam, Zahra Salehi; Ansari, Mohammad Javed; Jalil, Abduladheem Turki; Matencio Duran, Adrian; Trotta, Francesco; Yeganeh, Faten Eshrati; Farasati Far, Bahareh; Arki, Mandana Kazem; Naimi-Jamal, Mohammad Reza; Noorbazargan, Hassan; Lalami, Zahra Asghari; Chiani, Mohsen
File in questo prodotto:
File Dimensione Formato  
molecules-27-04634.pdf

Accesso aperto

Tipo di file: PDF EDITORIALE
Dimensione 3.51 MB
Formato Adobe PDF
3.51 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1872338
Citazioni
  • ???jsp.display-item.citation.pmc??? 9
  • Scopus 39
  • ???jsp.display-item.citation.isi??? 34
social impact